The urgent need for implementation science to achieve hepatitis C elimination

Affiliations

¹ Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2M7, Canada; Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, CIUSSS West-Central Montreal, Montreal, QC, Canada; Centre for Implementation Research, Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Kirby Institute, UNSW Sydney, Kensington, NSW, Australia. Electronic address: guil.fontaine@mcgill.ca.
² School of Population Health, UNSW Sydney, Kensington, NSW, Australia.
³ Research Centre, Université de Montréal Hospital Centre, Montreal, QC, Canada; Department of Family and Emergency Medicine, Université de Montréal, Montreal, QC, Canada.
⁴ Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
⁵ Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, CIUSSS West-Central Montreal, Montreal, QC, Canada; Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada.
⁶ School of Nursing, York University, North York, ON, Canada.
⁷ Department of Public Health Sciences, Queen's University, Kingston, ON, Canada.
⁸ Kirby Institute, UNSW Sydney, Kensington, NSW, Australia.
⁹ Centre for Implementation Research, Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Epidemiology and Public Health and School of Psychology, University of Ottawa, Ottawa, ON, Canada.

PMID: 40054488
DOI: 10.1016/S2468-1253(25)00050-0

The urgent need for implementation science to achieve hepatitis C elimination

Guillaume Fontaine et al. Lancet Gastroenterol Hepatol. 2025 Jun.

. 2025 Jun;10(6):498-502.

doi: 10.1016/S2468-1253(25)00050-0. Epub 2025 Mar 4.

Authors

Affiliations

¹ Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2M7, Canada; Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, CIUSSS West-Central Montreal, Montreal, QC, Canada; Centre for Implementation Research, Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Kirby Institute, UNSW Sydney, Kensington, NSW, Australia. Electronic address: guil.fontaine@mcgill.ca.
² School of Population Health, UNSW Sydney, Kensington, NSW, Australia.
³ Research Centre, Université de Montréal Hospital Centre, Montreal, QC, Canada; Department of Family and Emergency Medicine, Université de Montréal, Montreal, QC, Canada.
⁴ Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
⁵ Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, CIUSSS West-Central Montreal, Montreal, QC, Canada; Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada.
⁶ School of Nursing, York University, North York, ON, Canada.
⁷ Department of Public Health Sciences, Queen's University, Kingston, ON, Canada.
⁸ Kirby Institute, UNSW Sydney, Kensington, NSW, Australia.
⁹ Centre for Implementation Research, Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Epidemiology and Public Health and School of Psychology, University of Ottawa, Ottawa, ON, Canada.

PMID: 40054488
DOI: 10.1016/S2468-1253(25)00050-0

No abstract available

PubMed Disclaimer

Conflict of interest statement

JG and JP are co-senior authors. GF declares funding from the Canadian Institutes of Health Research (CIHR), and speaker fees from AbbVie. JB declares consulting fees from AbbVie and Gilead Sciences; speaker fees from Gilead Sciences; and receipt of equipment, materials, and drugs from Gilead Sciences for topics outside the scope of this Comment but broadly related to access to treatment and HCV elimination. NK declares funding from the CIHR. MJB declares funding from AbbVie, Gilead Sciences, and Cepheid, and speaker fees from Gilead Sciences and AbbVie. MBK declares funding and consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare. SS declares speaker fees from Novo Nordisk. JG declares funding from AbbVie, bioLytical Laboratories, Cepheid, Gilead Sciences, and Hologic, and speaker fees from AbbVie, Abbott, Cepheid, Gilead Sciences, and Roche. JP declares speaker and travel fees from CanVector, participation on the Ontario Immunization Advisory Committee, and leadership in the Canadian Psychological Association. CG and NT declare no competing interests.

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The urgent need for implementation science to achieve hepatitis C elimination

Affiliations

The urgent need for implementation science to achieve hepatitis C elimination

Authors

Affiliations

Conflict of interest statement

LinkOut - more resources

Full Text Sources